What is Lakewood-Amedex Biotherapeutics, Inc. (LABT)?

Lakewood-Amedex Biotherapeutics, Inc. (LABT) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of LABT?

The current price of LABT is $0.24. Prices are updated in real time on Stocks360.

What is LABT's price-to-earnings (PE) ratio?

LABT's trailing twelve-month PE ratio is -0.02, based on current price and earnings per share data available on Stocks360.

What is LABT's market capitalization?

LABT's market capitalization is $415,431.00, placing it in the small-cap tier.

Lakewood-Amedex Biotherapeutics, Inc. (LABT)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$0.24

Market Cap

$415.43K

PE (TTM)

-0.02

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-4.76

Day Range

$0.22 – $0.24

52-wk Range

$0.22 – $98.20

Avg Volume

N/A

Volume

3.91M

Lakewood-Amedex Biotherapeutics, Inc. (LABT) is a publicly traded company in the Healthcare sector. Latest price: $0.24. Market cap $415.43K. Trailing PE -0.02. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 5 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2026-04-23 · $86.50 2026-10-29 · $0.24 (-99.73%)

Earnings

Most Recent

Aug 13, 2026

EPS $-2.75 vs est. $-2.66

Missed by $0.09

Next Earnings

Nov 12, 2026

EPS estimate $-1.33

Proprietary Signals

Signal snapshot temporarily unavailable.

About Lakewood-Amedex Biotherapeutics, Inc.

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.02×
P/S (TTM)	0.00×
P/B	0.08×
PEG	0.00×
P/FCF (TTM)	-0.12×
EV / EBITDA	0.29×
EV / Sales	0.00×
Earnings Yield	-2180.81%
Free Cash Flow Yield	-839.07%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$2.07M
Net Income (TTM)	-$9.06M
Free Cash Flow (TTM)	-$3.36M
Net Debt	-$2.48M
Working Capital	$4.22M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	1687.68%
Return on Invested Capital	-163.98%